The application of immune checkpoint inhibitors (ICIs), targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) pathways, holds immense promise for cancer treatment. Here, CD274 is linked to cancer.